Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henk M Lokhorst

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Expert Opinion on Pharmacotherapy|June 1, 2013
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patientsNiels W C J van de Donk, Henk M Lokhorst
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2008
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 yearsCynthia Huisman, Ellen Meijer, Eefke J Petersen, et al.
Ocular Immunology and Inflammation|October 10, 2013
Absence of intraocular infections after hematopoietic stem cell transplantation at a single center: the experience with current preventive regimensElena I Stoyanova, Anjo Riemens, Henk M Lokhorst, et al.
Drugs|December 1, 2017
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An UpdateInger S Nijhof, Niels W C J van de Donk, Sonja Zweegman, et al.
Therapeutic Advances in Hematology|February 6, 2019
Immunotherapy in myeloma: how far have we come?Laurens E Franssen, Tuna Mutis, Henk M Lokhorst, et al.
Haematologica|July 6, 2005
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practiceKa Lung Wu, Wessel van Wieringen, Edo Vellenga, et al.
Blood|July 28, 2012
How I treat plasma cell leukemiaNiels W C J van de Donk, Henk M Lokhorst, Kenneth C Anderson, et al.
The Annals of Otology, Rhinology, and Laryngology|September 30, 2004
Laryngeal amyloidosis: localized versus systemic disease and update on diagnosis and therapyHilke Bartels, Frederik G Dikkers, Jacqueline E van der Wal, et al.
Current Pharmaceutical Design|February 4, 2006
New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathwayNiels W C J van de Donk, Andries C Bloem, Ellen van der Spek, et al.
Blood|July 12, 2003
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levelsNiels W C J van de Donk, Marloes M J Kamphuis, Berris van Kessel, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Expert Opinion on Pharmacotherapy|June 1, 2013
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patientsNiels W C J van de Donk, Henk M Lokhorst
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2008
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 yearsCynthia Huisman, Ellen Meijer, Eefke J Petersen, et al.
Ocular Immunology and Inflammation|October 10, 2013
Absence of intraocular infections after hematopoietic stem cell transplantation at a single center: the experience with current preventive regimensElena I Stoyanova, Anjo Riemens, Henk M Lokhorst, et al.
Drugs|December 1, 2017
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An UpdateInger S Nijhof, Niels W C J van de Donk, Sonja Zweegman, et al.
Therapeutic Advances in Hematology|February 6, 2019
Immunotherapy in myeloma: how far have we come?Laurens E Franssen, Tuna Mutis, Henk M Lokhorst, et al.
Haematologica|July 6, 2005
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practiceKa Lung Wu, Wessel van Wieringen, Edo Vellenga, et al.
Blood|July 28, 2012
How I treat plasma cell leukemiaNiels W C J van de Donk, Henk M Lokhorst, Kenneth C Anderson, et al.
The Annals of Otology, Rhinology, and Laryngology|September 30, 2004
Laryngeal amyloidosis: localized versus systemic disease and update on diagnosis and therapyHilke Bartels, Frederik G Dikkers, Jacqueline E van der Wal, et al.
Current Pharmaceutical Design|February 4, 2006
New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathwayNiels W C J van de Donk, Andries C Bloem, Ellen van der Spek, et al.
Blood|July 12, 2003
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levelsNiels W C J van de Donk, Marloes M J Kamphuis, Berris van Kessel, et al.
Pageof 9